朱雨亭

[摘要] 目的 研究氨磺必利与氟哌啶醇治疗精神分裂症临床疗效及安全性对照。 方法 以我院2012年6月～2014年1月精神分裂症患者160例随机分两组。氨磺必利组采用氨磺必利治疗，氟哌啶醇组采用氟哌啶醇治疗。比较两组患者精神分裂症治疗总有效率；治疗第8周用不良反应症状量表（TESS）评估不良反应发生情况；施行治疗前和治疗第8周患者精神病简明评定量表（BPRS）、阳性和阴性症状量表（PANSS）的差异。 结果 氨磺必利组患者精神分裂症治疗总有效率高于氟哌啶醇组（P<0.05）；氨磺必利组不良反应发生情况少于氟哌啶醇组（P<0.05）；施行治疗前两组BPRS评分和PANSS评分比较无显著差异（P>0.05）；治疗第8周氨磺必利组BPRS评分和PANSS评分改善幅度更大（P<0.05）。 结论 氨磺必利治疗精神分裂症临床疗效及安全性均高于氟哌啶醇，可有效减少不良反应的发生，促进患者阳性和阴性症状的改善，值得推广。

[关键词] 氨磺必利；氟哌啶醇；精神分裂症；安全性

[中圖分类号] R749.3 [文献标识码] A [文章编号] 2095-0616（2017）12-36-03

Control study on the clinical efficacy and safety of sulforamethrin and haloperidol in the treatment of schizophrenia

ZHU Yuting

Department of Psychiatry Ward IV， Meizhou Third People 's Hospital， Guangdong， Meizhou 514000， China

[Abstract] Objective To study the clinical efficacy and safety of sulforubicin and haloperidol in the treatment of schizophrenia. Methods 160 patients with schizophrenia cured in our hospital from June 2012 to January 2014 were randomly divided into two groups. Patients in sulforamid group were treated with sulforubicin， and patients in haloperidol group were treated with haloperidol. The total effective rate of schizophrenia was compared between the two groups. The incidence of adverse events was assessed by the Adverse Reaction Symptom Scale （TESS） at the 8th week of treatment. Before treatment and 8th weeks after treatment，the Psychiatric Simple Assessment Scale （BPRS） and the negative symptom scale （PANSS）. Results The total effective rate of schizophrenia in the sulforamid group was significantly higher than that in the haloperidol group （P<0.05）. The incidence of adverse reactions in the sulforamid group was less than that in the haloperidol group （P<0.05） There was no significant difference in the scores of BPRS and PANSS between the two groups before and after treatment （P>0.05）. The BPRS score and PANSS score in the sulforamid group were significantly higher （P<0.05）. Conclusion The efficacy and safety of sulforamide in the treatment of schizophrenia is higher than the haloperidol. It can effectively reduce the occurrence of adverse reactions， and promote the improvement of positive and negative symptoms.

[Key words] Sulfadiazole； Haloperidol； Schizophrenia； Safety

精神分裂症为临床常见精神疾病，在治疗上主要有典型和非典型抗精神病药物两种[1]，本研究对氨磺必利与氟哌啶醇治疗精神分裂症临床疗效及安全性对照进行分析，现报道如下。

1 资料与方法

1.1 一般资料

以我院2012年6月～2014年1月精神分裂症患者160例随机分两组。患者年龄18～60岁，

病程在3个月～20年间。所有患者符合精神分裂症诊断标准，在入组前1个月内未使用长效抗精神病药物治疗，入组时两组的阳性和阴性症状量表（PANSS）评分均≥60分，所有患者体重指数在24.9以内，无合并躯体严重疾病或脑部器质性疾病、神经系统疾病。除外妊娠期、哺乳期妇女、药物依赖、滥用和其他精神活性药物使用史的患者、对本研究药物过敏者。

氨磺必利组患者男45例，女35例；18～60岁，年龄（36.12±2.13）岁。发病时间3个月～20年，平均（8.21±4.29）年。……